



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/843,159
Filing Date	April 25, 2001
First Named Inventor	LUO, Ying
Art Unit	1652
Examiner Name	RAO, M.
Attorney Docket Number	A-68292-2/RMS/DHR; 467802-217

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MR	A4	US- 6,455,290 B1	09/24/2002	Berthelsen et al.	
MR	A5	US- 6,277,613 B1	08/21/2001	De Lange et al.	
MR	A6	US- 6,387,902 B1	05/14/2002	Zhang et al.	
		US-			
		US-	/Manjunath Rao/ (05/23/2006)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

COPY

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
MR	B8	WO	01/04326 A1	01/18/2001	Berthelsen et al.		<input type="checkbox"/>	<input type="checkbox"/>
MR	B9	WO	00/77225 A1	12/21/2000	Chi et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Manjunath Rao/ (05/23/2006)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/843,159

Filing Date

April 25, 2001

First Named Inventor

LUO, Ying

Art Unit

1652

Examiner Name

RAO, M.

Sheet

2

of

2

Attorney Docket Number

A-68292-2/RMS/DHR; 467802-217

## OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MR	C27	DECKER, P. et al., "An Improved Nonisotopic Test to Screen a Large Series of New Inhibitor Molecules of Poly(ADP-ribose) Polymerase Activity for Therapeutic Applications," Clinical Cancer Research, 5:1169-1172, May 1999.	<input type="checkbox"/>	<input type="checkbox"/>
MR	C28	RANKIN, P.W. et al., "Quantitative Studies of Inhibitors of ADP-ribosylation <i>in Vitro</i> and <i>In Vivo</i> ," J. Biol. Chem., 264(8):4312-4317, March 1989.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

COPY

EXAMINER SIGNATURE /Manjunath Rao/ (05/23/2006)

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

5, no persons are required

**OFFICE OF  
CLOSURE  
PLANT**

**NOV 30 2003**

**PLANT & TRADEMARK OFFICE**

**Complete if Known**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

<b>Application Number</b>	09/843,159
<b>Filing Date</b>	April 25, 2001
<b>First Named Inventor</b>	Luo
<b>Group Art Unit</b>	1653
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	A-68292-2/RMS/DHR

Sheet	1	of	3
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	/Manjunath Rao/ (05/23/2006)	Date Considered	
-----------------------	------------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box.



COPY

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1999, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete If Known</b>			
		Application Number	09/843,159		
		Filing Date	April 25, 2001		
		First Named Inventor	Luo		
		Group Art Unit	1653		
		Examiner Name	Unknown		
Sheet	2	of	3	Attorney Docket Number	A-68292-2/RMS/DHR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MR	C1	Smith et al., "Tankyrase, a poly (ADP-ribose) polymerase at human telomeres," Science, 282(5393):1484-1487 (November 1998).	
	C2	Mera, S., "The role of telomeres in aging and cancer," Br J Biomed Sci, 55(3):221-225 (September 1998).	
	C3	Lux et al., "Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins," Nature, 344(6261):36-42 (March 1990).	
	C4	Bryan et al., "Telomerase and the maintenance of chromosome ends," Curr Opin Cell Biol, 11(3):318-324 (June 1999).	
	C5	Hiyama et al., "Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis," Virchows Arch, 434(6):483-487 (June 1999).	
	C6	Krejc, K., "An in situ study of variant telomeric repeats in human chromosomes," Genomics, 58(2):202-206 (June 1999).	
	C7	Holt et al., "Role of telomerase in cellular proliferation and cancer," J Cell Physiol, 180(1):10-18 (July 1999).	
	C8	Tan, Z., "Intramitotic and intraclonal variation in proliferative potential of human diploid cells: explained by telomere shortening," J Theor Biol, 198(2):259-268 (May 1999).	
	C9	Zhu et al., "Chromosomal mapping of the tankyrase gene in human and mouse", Genomics 57:320-321 (1999)	
	C10	Daly, "The Grb7 Family of Signalling Proteins," Cell. Signal 10(9):613-618 (1998)	
	C11	Janes, et al., "Structural Determinants of the Interaction between the erbB2 Receptor and the Src Homology 2 Domain of Grb7," J Biol Chem 272(13):8490-8497 (1997)	
	C12	Daly, "Take Your Partners, Please - Signal Diversification by the erbB Family of Receptor Tyrosine Kinases," Growth Factors 16:255-263 (1999)	
	C13	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science 247:1306-1310 (1990)	
	C14	Burgess et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," J Cell Bio. 111(5 pt 1):2129-2138 (1990)	
	C15	Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," Nat Genet 21(4):440-443 (1999)	
	C16	Bork, P., "Powers and Pitfalls in sequence analysis: the 70% hurdle," Genome Res 10(4):398-400 (2000)	
MR	C17	Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular 4th Ed., Springer-Verlay, Berlin, pp. 17-18 (1976)	

Examiner Signature	/Manjunath Rao/ (05/23/2006)	Date Considered	
--------------------	------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ☐



PTO/SB/8B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/843,159		
		Filing Date	April 25, 2001		
		First Named Inventor	Luo		
		Group Art Unit	1653		
		Examiner Name	Unknown		
Sheet	3	of	3	Attorney Docket Number	A-68292-2/RMS/DHR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MR ↓	C18	Lazar, et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," Mol Cell Biol 8(3):1247-1252 (1988)	
	C19	Harris et al., "Polycystic kidney disease. 1: Identification and analysis of the primary defect," J Am Soc Nephrol 6(4):1125-1133 (1995)	
	C20	Ahn, et al., "The structural and functional diversity of dystrophin," Nat Genet 3(4):283-291 (1993)	
	C21	Cawthon et al., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," Genomics 9(3):446-460 (1991)	
	C22	Database SWALL:CGA1_XENLA, accession P18606 (Nov. 1990), Cyclin A1	
	C23	Database SWALL:CGB1_XENLA, accession P13350 (Jan 1990), G2/Mitotic-specific Cyclin B1	
	C24	Database SWALL:CGB1_HUMAN, accession P14635 (Apr 1990), G2/Mitotic-specific Cyclin B1	
	C25	Database EMBL:MMAA24592, accession AA124592 (Nov 1996), mp86g12.r1 Soares_thymus_2NbMT Mus musculus cDNA clone similar to gb:M25753 G2/Mitotic-specific Cyclin B1 (Human)	
	C26	Database EMBL:HSZZ78609, accession AA373339 (Apr 1997), EST85503 HSC172 cells I Homo sapiens cDNA 5' end similar to cyclin B, mRNA sequence	

Examiner Signature	/Manjunath Rao/ (05/23/2006)	Date Considered	
--------------------	------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	10/616,101
		Filing Date	July 8, 2003
		First Named Inventor	LUO, YING
		Art Unit	1642
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	RIGL-010CIP3	

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				


OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MR		FUKUSHIMA et al., POLY (ADP-RIBOSE) SYNTHESIS IN HUMAN CERVICAL CANCER CELL-DIAGNOSTIC CYTOLOGICAL USEFULNESS, Cancer Letters, 1981, 14: 227-236	

Examiner Signature	/Manjunath Rao/ (05/23/2006)	Date Considered	
--------------------	------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/616,101
Sheet 1 of 1				Filing Date	July 8, 2003
				First Named Inventor	Luo et al.
				Art Unit	1652
				Examiner Name	Rao, Manjunath N.
				Attorney Docket Number	Tankyrase H, compositions involved in the cell cycle and methods of use

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
MR		US20030211462	Nov. 13, 2003	SHEN	

Examiner Signature	/Manjunath Rao/ (05/23/2006)	Date Considered	
-----------------------	------------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.